Trial reportContemporary clinical trials2016
Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND).
Trial report in Contemporary clinical trials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02358343 (ASCEND), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ASCEND: A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Interventions for fatigue in people with kidney failure requiring dialysis.The Cochrane database of systematic reviews · 2023Pooled it
- Psychosocial interventions for preventing and treating depression in dialysis patients.The Cochrane database of systematic reviews · 2019Pooled it
- Design and Baseline Characteristics of CONCORD, a Trial of Novel Therapies for Depression in CKD.Kidney international reports · 2026Article
- A new self-management engagement scale for haemodialysis patients (PRIESM CKD-HD): development and validation.Clinical kidney journal · 2026Article
- Risk Factors for Fatigue in Adults Receiving Maintenance Hemodialysis Who Have Chronic Pain: A Secondary Analysis of the HOPE Consortium Trial.Kidney medicine · 2026Article
- Safety and efficacy of sertraline in depression among adults undergoing dialysis: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024Article
- Pharmacological and psychological treatment of depression and anxiety among hemodialyzed patients - a review.Postepy psychiatrii neurologii · 2024Review
- Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.Clinical kidney journal · 2023Review
- Anxiety and Response to Treatment of Depression in People Undergoing Maintenance Hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2023Article
- Patient-centred clinical trial design.Nature reviews. Nephrology · 2022Review
- Effect of Probiotic Supplements on Oxidative Stress Biomarkers in First-Episode Bipolar Disorder Patients: A Randomized, Placebo-Controlled Trial.Frontiers in pharmacology · 2022Article
- Pharmacologic and psychological interventions for depression treatment in patients with kidney disease.Current opinion in nephrology and hypertension · 2020Review
- Technology-assisted cognitive-behavioral therapy intervention for end-stage renal disease.Translational behavioral medicine · 2020Article
- ASCENDing to New Heights in Our Understanding of the Treatment of Depression Among Individuals Receiving Hemodialysis.Annals of internal medicine · 2019Article
- Patterns and predictors of depression treatment among adults with chronic kidney disease and depression in ambulatory care settings in the United States.International urology and nephrology · 2019Article
- Neuropsychiatric Disorders in Chronic Kidney Disease.Frontiers in pharmacology · 2019Review
- Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management.Kidney international reports · 2017Review
- Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes.American journal of nephrology · 2016Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 11 institutions in 1 country.
Funding
Abstract
Major Depressive Disorder (MDD) is highly prevalent in patients with End Stage Renal Disease (ESRD) treated with maintenance hemodialysis (HD). Despite the high prevalence and robust data demonstrating an independent association between depression and poor clinical and patient-reported outcomes, MDD is under-treated when identified in such patients. This may in part be due to the paucity of evidence confirming the safety and efficacy of treatments for depression in this population. It is also unclear whether HD patients are interested in receiving treatment for depression. ASCEND (Clinical Trials Identifier Number NCT02358343), A Trial of Sertraline vs. Cognitive Behavioral Therapy (CBT) for End-stage Renal Disease Patients with Depression, was designed as a multi-center, 12-week, open-label, randomized, controlled trial of prevalent HD patients with comorbid MDD or dysthymia. It will compare (1) a single Engagement Interview vs. a control visit for the probability of initiating treatment for comorbid depression in up to 400 patients; and (2) individual chair-side CBT vs. flexible-dose treatment with a selective serotonin reuptake inhibitor, sertraline, for improvement of depressive symptoms in 180 of the up to 400 patients. The evolution of depressive symptoms will also be examined in a prospective longitudinal cohort of 90 HD patients who choose not to be treated for depression. We discuss the rationale and design of ASCEND, the first large-scale randomized controlled trial evaluating efficacy of non-pharmacologic vs. pharmacologic treatment of depression in HD patients for patient-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.